Navigation Links
Clinical Update - Debio 025 in Hepatitis C
Date:4/28/2009

ards patients continued treatment on Peg-IFN alpha-2a and Ribavirin. A loading dose of Debio 025 at the start of treatment accelerates the onset of action and enhances efficacy in the early stage of treatment.

About Debio 025

Debio 025 is a synthetic first-in-class Cyp inhibitor, being tested in humans as a potential anti-HCV drug. Debio 025 binds strongly to Cyp, host cell proteins thought to confer a replication advantage to HCV. Its potent inhibitory activity on the HCV replication was shown in the following clinical studies. Results of a phase Ib study demonstrate that Debio 025 monotherapy for 15 days induced a strong anti-HCV effect (3.6 log10 reduction) in HIV-1/HCV co-infected patients. (Hepatology, 47:817-26). Results of a phase IIa study with Debio 025 indicate that Debio 025 shows an important additive anti-HCV effect (4.6 log10 reduction) when co-administered with peg-IFN(alpha)2a to treatment-naive HCV patients. (Hepatology, in press)

About HCV

Globally, an estimated 170 million persons are chronically infected with HCV and 3 to 4 million are newly infected each year. HCV, in combination with hepatitis B, now accounts for 75% of all cases of liver disease around the world. HCV is considered by the World Health Organization as an epidemic. Because HCV can infect a patient for decades before being discovered, it is often called the "silent" epidemic. Studies suggest that in the US alone, nearly 4 million people are or have been infected with HCV and of these, 2.7 million have an ongoing chronic infection, the majority being between 40 to 60 years old.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to phar
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
4. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
5. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
6. Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer
7. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
8. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
9. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
10. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
11. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014  Formex, LLC ("Formex"), a leader in ... Weilersbacher joined Formex as Director of Quality ... Greg Weilersbacher has over 20 ... in Quality Assurance, Facility Validation, GMP manufacturing, and ... to Formex a diverse wealth of experience. ...
(Date:9/16/2014)... 2014 On September 25 to 26, 2014, ... medical design and manufacturing - MEDTEC China  - will ... Exhibition & Convention Center, bringing together close to 300 ... showcase their latest medical-grade raw materials, parts and processing ... remaining for free visitor pre-registration to be completed. To ...
(Date:9/16/2014)... 16, 2014 CorMedix Inc. ("CorMedix") (NYSE ... and commercializing therapeutic products for the prevention and ... the amendment and restatement of its outstanding Series ... related warrants, as well as the warrants issued ... financing, to remove anti-dilution, price reset and certain ...
Breaking Medicine Technology:Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3
... , , STAMFORD, ... Zargis Medical, a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE ... New Product Awards on February 11th—the 163rd birthday of renowned inventor ... in New York City . Edison created many of the ...
... Rowinsky to Serve on RRD International,s Product Advisory ... 17 RRD International, a strategy-driven biotech and ... Rowinsky , M.D. will oversee oncology product development, serving ...  Dr. Rowinsky is a highly accomplished cancer therapeutics expert ...
Cached Medicine Technology:Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards 2Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards 3Cancer Expert Dr. Eric Rowinsky to Oversee Oncology Product Development at RRD International 2Cancer Expert Dr. Eric Rowinsky to Oversee Oncology Product Development at RRD International 3
(Date:9/16/2014)... therapy and radiation therapy as part of breast ... women with hormone-receptor positive (HR+) invasive breast cancer. ... Cancer Center, however, shows that combination may not ... disease. , The results, which Fox Chase ... Oncology,s 56th Annual Meeting on Sunday, September 14, ...
(Date:9/16/2014)... 2014 Programs and policies that promote ... billions of dollars in savings for the US health ... Fund. To help spur these types of improvements, the ... collaborative groups from across the country to field test ... - a handbook designed to assist groups working together ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Who:, The ... Anschutz Medical Campus and Children’s Hospital Colorado ... is the country’s leading pulmonary hypertension association that works to ... a disease of the lungs that affects the functioning of ... treatment, mean survivability is only 2.8 years. , What:, ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, 2014 ... objective scientific way to diagnose major depression in adults, a ... nine genetic indicators (known as "RNA markers") in the blood. ... cognitive behavioral therapy, one of the most common and effective ... Northwestern University researchers report. Depression affects nearly 7 percent ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, ... U.S. cancer survivors are alive today, compared to just ... Research reported Tuesday. These individuals amount to 4 ... of childhood cancer, according to the association,s annual progress ... and treatment of cancer and details some of the ...
Breaking Medicine News(10 mins):Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:NQF Seeks Field Testing Groups for Population Health Guide 2Health News:NQF Seeks Field Testing Groups for Population Health Guide 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2Health News:Blood Test Spots Adult Depression: Study 2Health News:Blood Test Spots Adult Depression: Study 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4
... ... to familiarize themselves with the draft of the new Diagnostic and Statistical Manual (DSM), ... mental disorders in children and adults. , ... Arlington, VA (PRWEB) February 12, 2010 -- The National Alliance ...
... , MISSION VIEJO, Calif. , Feb. 12 ... the parent company of the Ensign™ group of skilled nursing, ... today that it expects to issue its fourth quarter and ... Wednesday, February 17, 2010 . , (Logo:   http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ...
... , PITTSBURGH , Feb. 12 ... launched its free antibiotics program in September of 2009, and ... more than $3 million in free prescriptions for ... more than 590,000 prescriptions for free antibiotics have been filled ...
... , BEAVER, Penn. , Feb. 12 ... UMPS CARE Charities, are proud to announce that the 5th Annual UMPS ... in need. , NNDS and SlateXP are proud to support the ongoing ... umpires. The funds raised at the Golf Classic ensure that umpires will ...
... Feb. 12 Making healthy choices can be a difficult ... Northwest and Intermountain Region continues to support its community by offering ... health care system and rewards for living healthier – all through ... the latter half of 2009, myRegence.com earned 17 key ...
... 12, 2010Hypnosis has potential therapeutic value in children with ... or unexplained sensations of difficulty breathing and for lessening ... hypnosis as an adjunct to conventional treatment and its ... physiological changes are explored in a provocative paper in ...
Cached Medicine News:Health News:NAMI Encourages DSM-5 Discussion 2Health News:The Ensign Group Schedules Year-End 2009 Earnings Call for Thursday, February 18, 2010 2Health News:Giant Eagle Pharmacy Free Antibiotics Program Surpasses $3 Million in Free Prescriptions 2Health News:National Network of Digital Schools, SlateXP and UMPS CARE Raise $75,000 for Children 2Health News:National Network of Digital Schools, SlateXP and UMPS CARE Raise $75,000 for Children 3Health News:Industry Recognizes the Regence Health Engine for Excellence in Creativity, Innovation and Information 2Health News:Industry Recognizes the Regence Health Engine for Excellence in Creativity, Innovation and Information 3Health News:Hypnosis can relieve symptoms in children with respiratory diseases 2
... The QuickLink™ Delivery System ... device designed to assemble ... SourceLink Connectors into seed ... and with variable seed ...
... is the first one-step 20 minutes rapid test ... 2 produced by Enterohemorrhagic Escherichia coli in human ... enrichment of fecal specimens and detects all Toxigenic ... separate result for Toxin 1 and 2 is ...
Classic, stylish, and preppy, this collection features men's, women's and unisex styles....
The Claiborne brand provides the perfect look for the man who wants to be comfortable and relaxed, yet look appropriate for each occasion....
Medicine Products: